Description
Molvir 200Mg - Anti-COVID Generic Drug Molnupiravir
Indication:
Indicated
for the treatment of mild to moderate coronavirus disease 2019
(COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who
have at least one risk factor for developing severe illness.
Dosage & Administration:
The recommended dose is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days
Preparation:
Each box contains 10 capsules in blister pack.
Additional Information
Molnupiravir is the world’s first oral pill to treat symptomatic COVID-19 which was approved by the UK’s Medicines and Healthcare products Regulatory Agency on 4 November 2021. Molnupiravir is originally developed by the US based pharma major Merck, Sharp & Dohme (MSD) and Ridgeback Biotherapeutics.
